Nortem BioGroup (EPA:MLBIO)

Nortem BioGroup Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
Revenue	5.22	3.28	1.52
Revenue Growth (YoY)	59.41%	115.01%	-
Cost of Revenue	0.91	0.62	0.34
Gross Profit	4.31	2.65	1.19
Selling, General & Admin	0.4	0.12	0.18
Other Operating Expenses	2.9	2.04	0.95
Operating Expenses	3.87	2.58	1.12
Operating Income	0.44	0.07	0.06
Interest & Investment Income	0	-	0
Other Non Operating Income (Expenses)	-0.26	-0.02	-0.03
Pretax Income	0.18	0.06	0.03
Income Tax Expense	0.05	0.01	0.01
Earnings From Continuing Operations	0.14	0.04	0.03
Net Income	0.14	0.04	0.03
Net Income Growth	212.27%	70.74%	-
Gross Margin	82.51%	81.00%	77.88%
Operating Margin	8.50%	2.29%	4.16%
Profit Margin	2.64%	1.35%	1.70%
EBITDA	1.01	0.49	-
EBITDA Margin	19.36%	15.02%	-
EBIT	0.44	0.07	0.06
EBIT Margin	8.50%	2.29%	4.16%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.